高级检索

Lp(a)离成为下一个干预靶点还有多远

, 

上一篇

下一篇

文章导航 > 临床心血管病杂志 > 2023 > 39(9): 664-666
陈桢玥, 孙燕依. Lp(a)离成为下一个干预靶点还有多远[J]. 临床心血管病杂志, 2023, 39(9): 664-666. doi: 10.13201/j.issn.1001-1439.2023.09.003
引用本文: 陈桢玥, 孙燕依. Lp(a)离成为下一个干预靶点还有多远[J]. 临床心血管病杂志, 2023, 39(9): 664-666. doi: 10.13201/j.issn.1001-1439.2023.09.003
shu
CHEN Zhenyue, SUN Yanyi. How far is Lp(a) from becoming the next intervention target?[J]. J Clin Cardiol, 2023, 39(9): 664-666. doi: 10.13201/j.issn.1001-1439.2023.09.003
Citation: CHEN Zhenyue, SUN Yanyi. How far is Lp(a) from becoming the next intervention target?[J]. J Clin Cardiol, 2023, 39(9): 664-666. doi: 10.13201/j.issn.1001-1439.2023.09.003
shu

Lp(a)离成为下一个干预靶点还有多远

    • 上海交通大学医学院附属瑞金医院(上海，200025)

详细信息

How far is Lp(a) from becoming the next intervention target?

    • Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China

More Information

    摘要
  • 脂蛋白(a)[Lp(a)]升高是低密度脂蛋白胆固醇(LDL-C)以外的动脉粥样硬化性心血管疾病(ASCVD)的独立危险因素。Lp(a)的致动脉粥样硬化特性与其结构、组分密切相关。然而，关于Lp(a)的检测方法、风险增加切点及起始干预切点、特异性干预手段尚存在诸多困惑。干预Lp(a)是否能带来心血管获益的硬终点研究正在进行。Lp(a)能否成为下一个心血管风险干预靶标值得期待。
    Elevated lipoprotein (a)[Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) other than low-density lipoprotein cholesterol (LDL-C). The atherogenic properties of Lp(a) are closely related to its structure and components. Yet, there remains puzzling issues related to Lp(a) assays, cut-points for increased risk and initial treatment, and specific means of Lp(a) interventions. The endpoint study of whether intervention with Lp(a) results in cardiovascular benefit is in progress. It is anticipated whether Lp(a) will be the next target for cardiovascular risk intervention.
    • HTML全文
  • 加载中
    • 参考文献(27)
  • [1]

    Berg K. A new serum type system in man-the Lp system[J]. Acta Pathol Microbiol Scand, 1963, 59: 369-382.

    [2]

    Dahlén G, Ericson C, Furberg C, et al. Studies on an extra pre-beta lipoprotein fraction[J]. Acta Med Scand Suppl, 1972, 531: 1-29.

    [3]

    Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies[J]. J Am Coll Cardiol, 2017, 69(6): 692-711. doi: 10.1016/j.jacc.2016.11.042

    [4]

    Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a)and increased risk of myocardial infarction[J]. JAMA, 2009, 301(22): 2331-2339. doi: 10.1001/jama.2009.801

    [5]

    Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a)in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association[J]. J Clin Lipidol, 2019, 13(3): 374-392. doi: 10.1016/j.jacl.2019.04.010

    [6]

    Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on Lipoprotein(a): A call to action[J]. Atherosclerosis, 2019, 291: 62-70. doi: 10.1016/j.atherosclerosis.2019.10.011

    [7]

    Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a)as a predictor of coronary heart disease: the PRIME Study[J]. Atherosclerosis, 2002, 163(2): 377-384. doi: 10.1016/S0021-9150(02)00026-6

    [8]

    Alonso R, Andres E, Mata N, et al. Lipoprotein(a)levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation[J]. J Am Coll Cardiol, 2014, 63(19): 1982-1989. doi: 10.1016/j.jacc.2014.01.063

    [9]

    Zawacki AW, Dodge A, Woo KM, et al. In pediatric familial hypercholesterolemia, lipoprotein(a)is more predictive than LDL-C for early onset of cardiovascular disease in family members[J]. J Clin Lipidol, 2018, 12(6): 1445-1451. doi: 10.1016/j.jacl.2018.07.014

    [10]

    Zhang M, Liu HH, Jin JL, et al. Lipoprotein(a)and cardiovascular death in oldest-old(≥80 years)patients with acute myocardial infarction: A prospective cohort study[J]. Atherosclerosis, 2020, 312: 54-59. doi: 10.1016/j.atherosclerosis.2020.08.033

    [11]

    Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a)lipoprotein level and coronary disease[J]. N Engl J Med, 2009, 361(26): 2518-2528. doi: 10.1056/NEJMoa0902604

    [12]

    Liu YB, Ma HK, Zhu Q, et al. A genome-wide association study on lipoprotein(a)levels and coronary artery disease severity in a Chinese population[J]. J Lipid Res, 2019, 60(8): 1440-1448. doi: 10.1194/jlr.P091009

    [13]

    Marcovina SM, Moriarty PM, Koschinsky ML, et al. JCL roundtable-Lipoprotein(a): The emerging risk factor[J]. Clin Lipidol, 2018, 12(6): 1335-1345. doi: 10.1016/j.jacl.2018.11.003

    [14]

    Marcovina SM, Albers JJ. Lipoprotein(a)measurements for clinical application[J]. J Lipid Res, 2016, 57(4): 526-537. doi: 10.1194/jlr.R061648

    [15]

    北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167. doi: 10.3969/j.issn.1000-3614.2021.12.003

    [16]

    Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a)levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials[J]. Lancet, 2018, 392(10155): 1311-1320. doi: 10.1016/S0140-6736(18)31652-0

    [17]

    Liu HH, Cao YX, Jin JL, et al. Predicting Cardiovascular Outcomes by Baseline Lipoprotein(a)Concentrations: A Large Cohort and Long-Term Follow-up Study on Real-World Patients Receiving Percutaneous Coronary Intervention[J]. J Am Heart Assoc, 2020, 9(3): e014581. doi: 10.1161/JAHA.119.014581

    [18]

    Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a)as a cardiovascular risk factor: current status[J]. Eur Heart J, 2010, 31(23): 2844-2853. doi: 10.1093/eurheartj/ehq386

    [19]

    中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中国循环杂志, 2023, 38(3): 237-271. doi: 10.3969/j.issn.1000-3614.2023.03.001

    [20]

    Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a)to cardiovascular outcomes: the AIM-HIGH trial(Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes)[J]. J Am Coll Cardiol, 2013, 62(17): 1575-1579. doi: 10.1016/j.jacc.2013.06.051

    [21]

    O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk[J]. Circulation, 2019, 139(12): 1483-1492. doi: 10.1161/CIRCULATIONAHA.118.037184

    [22]

    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, et al. Lipoprotein(a)reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials[J]. Atherosclerosis, 2019, 288: 194-202. doi: 10.1016/j.atherosclerosis.2019.06.896

    [23]

    Szarek M, Bittner VA, Aylward P, et al. Lipoprotein(a)lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial[J]. Eur Heart J, 2020, 41(44): 4245-4255. doi: 10.1093/eurheartj/ehaa649

    [24]

    Sahebkar A, Reiner, Simental-Mendía LE, et al. Effect of extended-release niacin on plasma lipoprotein(a)levels: A systematic review and meta-analysis of randomized placebo-controlled trials[J]. Metabolism, 2016, 65(11): 1664-1678. doi: 10.1016/j.metabol.2016.08.007

    [25]

    Moriarty PM, Hemphill L. Lipoprotein Apheresis[J]. Endocrinol Metab Clin North Am, 2016, 45(1): 39-54. doi: 10.1016/j.ecl.2015.09.003

    [26]

    Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a)in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials[J]. Lancet, 2016, 388(10057): 2239-2253. doi: 10.1016/S0140-6736(16)31009-1

    [27]

    Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a)Reduction in Persons with Cardiovascular Disease[J]. N Engl J Med, 2020, 382(3): 244-255. doi: 10.1056/NEJMoa1905239

    • 相关文章
  • 施引文献
  • 资源附件(0)
  • 加载中
计量
  • 文章访问数:  1030
  • PDF下载数:  338
  • 施引文献:  0
出版历程
收稿日期:  2023-08-16
刊出日期:  2023-09-13

目录

    返回

    用微信扫描二维码

    分享至好友和朋友圈

    地址：

    邮政编码：

    电话：

    E-mail： lcxxgbzz@whuh.com

    {{newsColumn.name}}

    {{news.title}}

    版权所有 © 武汉协和医院杂志社 鄂ICP备 05004666-1 技术支持： 北京仁和汇智信息技术有限公司